Picture of Ovid Therapeutics logo

OVID — Ovid Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Ovid Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Ovid Therapeutics Inc  OVID.OQ  reported quarterly
adjusted
earnings of 12 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -18 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 22 cents per
share. Wall Street expected results to range from -26 cents
to -12 cents per share.
    * Revenue rose 125.3% to $169.00 thousand from a year ago;
analysts expected $70.00 thousand. 
    * Ovid Therapeutics Inc's reported EPS for the quarter was
12
cents​.
    * The company reported quarterly net income of $8.52
million.
    * Ovid Therapeutics Inc shares had risen by 9.8% this
quarter and
lost 73.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Ovid Therapeutics
Inc is $3.00 
This summary was machine generated from LSEG data August 13 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.22          0.12           Beat
 Mar. 31 2024      -0.22          -0.17          Beat
 Dec. 31 2023      -0.05          -0.22          Missed
 Sep. 30 2023      -0.19          -0.16          Beat

Recent news on Ovid Therapeutics

See all news